Strides Pharma Science
Strides Pharma Science Share Price Chart
Strides Pharma Science last traded at ₹1,095.00 (2026-10-13). Over the past month the stock moved -9.7%, three months the stock moved -6.3%, year the stock moved +25.8%. Its closing range over 52 weeks is ₹796.20 – ₹1,229.50, with the latest close 10.9% below the high.
Closing prices up to 2026-10-13.
About Strides Pharma Science
Strides Pharma Science Ltd is in the business of development and manufacturing of pharmaceutical products.[1] The company's pharmaceutical products are sold in over 100 countries.[2] The company has always followed an inorganic growth strategy over the years that resulted in foray into new markets, addition of new business segments, therapy segments and manufacturing infrastructure.[3]
Business Segments: a) Pharma Generics:[1] Its generic pharma business is driven by IP- based product licensing and global marketing and distribution partnerships. It specializes in manufacturing niche generic formulations in various dosage forms, like tablets, capsules, liquids, and sachets, focusing on regulated markets including the United States, Europe, Australia, etc. It has emerged as one of the world’s leading producers of soft gelatin capsules.[2] b) Branded Generics:[3] The company operates in the branded generics segment in Africa with an In Africa for Africa strategy. It offers a portfolio of branded generics for chronic therapies, including women’s health, CNS, cardiovascular, and diabetes treatments. Its established brands include Renerve, Unibrol, Combiart, Duotab, Vitafer, etc. c) Institutional Business: The company runs an institutional business catering to donor-funded markets, providing affordable treatments worldwide. It develops and manufactures drugs for anti-retroviral, anti-malarial, anti-tuberculosis, hepatitis, and other infectious diseases. These products are distributed to disease-prone regions across Africa, Asia, and Latin America, reaching 100+ countries. [4]
Fundamentals
Quarterly Results
In the latest quarter (Jun 2026), Strides Pharma Science reported sales of ₹1,265.00 crore (+12.9%) and net profit of ₹165.00 crore (+55.7%), compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 1,265 | 228.00 | 18.00 | 165.00 | 17.02 |
| Mar 2026 | 1,323 | 240.00 | 18.00 | 129.00 | 13.77 |
| Dec 2025 | 1,195 | 236.00 | 20.00 | 208.00 | 21.93 |
| Sep 2025 | 1,221 | 231.00 | 19.00 | 132.00 | 13.84 |
| Jun 2025 | 1,120 | 218.00 | 19.00 | 106.00 | 10.80 |
| Mar 2025 | 1,190 | 218.00 | 18.00 | 86.00 | 8.91 |
| Dec 2024 | 1,154 | 210.00 | 18.00 | 90.00 | 9.54 |
| Sep 2024 | 1,167 | 184.00 | 16.00 | 72.00 | 7.81 |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +16.8% | +14.7% | +14.0% | +6.3% | +4.6% | +3.6% | +11.2% | +12.9% |
| Operating profit growth | +65.8% | +62.8% | +29.0% | +16.0% | +25.5% | +12.4% | +10.1% | +4.6% |
| Net profit growth | – | +66.7% | +760.0% | -96.8% | +83.3% | +131.1% | +50.0% | +55.7% |
| EPS growth | – | +76.7% | +350.0% | -97.0% | +77.2% | +129.9% | +54.5% | +57.6% |
| OPM % | 16.0% | 18.0% | 18.0% | 19.0% | 19.0% | 20.0% | 18.0% | 18.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Annual Financials
In the latest year (Mar 2026), Strides Pharma Science reported sales of ₹4,859.00 crore (+6.4%) and net profit of ₹575.00 crore (-84.0%), compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 4,859 | 925.00 | 19.00 | 575.00 | 60.34 |
| Mar 2025 | 4,565 | 803.00 | 18.00 | 3,598 | 389.75 |
| Mar 2024 | 3,890 | 528.00 | 14.00 | -94.00 | -7.68 |
| Mar 2023 | 3,688 | 145.00 | 4.00 | -212.00 | -22.44 |
| Mar 2022 | 3,070 | -131.00 | -4.00 | -474.00 | -51.25 |
| Mar 2021 | 3,316 | 537.00 | 16.00 | 258.00 | 29.93 |
| Mar 2020 | 2,752 | 414.00 | 15.00 | 31.00 | 4.06 |
| Mar 2019 | 2,178 | 197.00 | 9.00 | 330.00 | 36.27 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | -23.4% | +26.4% | +20.5% | -7.4% | +20.1% | +5.5% | +17.4% | +6.4% |
| Operating profit growth | -50.5% | +110.2% | +29.7% | -124.4% | – | +264.1% | +52.1% | +15.2% |
| Net profit growth | -51.8% | -90.6% | +732.3% | -283.7% | – | – | – | -84.0% |
| EPS growth | -51.2% | -88.8% | +637.2% | -271.2% | – | – | – | -84.5% |
| OPM % | 9.0% | 15.0% | 16.0% | -4.0% | 4.0% | 14.0% | 18.0% | 19.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Shareholding
AI Analysis
No AI analysis generated yet for Strides Pharma Science.
Get Free AI Stock Analysis FREE →Latest News
-
Nana Patekar dies at 75: 10 iconic dialogues of the Bollywood star - The Economic Times
-
Star Imaging and Path Lab starts commercial operations of CT scan facility in Haryana
-
USFDA concludes cGMP inspection at formulations facility of Strides Pharma Science
-
Thalapathy Vijay's 'Jilla' co-star once earned just Rs 20 a day, couldn't afford Rs 1.25 bun, spent years - The Economic Times
-
Manoj Bajpayee shares the biggest sacrifice he made to become a star: 'Never spent more than 10 days with - The Economic Times
-
Ranveer Singh's 'Padmaavat' co-star Aditi Rao Hydari lives with Siddharth in a 4,000 sq ft Chennai home wi - The Economic Times
-
Strides Pharma Science - Abu Dhabi Investment Portfolio: 10 stocks rally up to 107% in CY26 - The Economic Times
-
Strides Pharma Science - Abu Dhabi Investment Portfolio: 10 stocks rally up to 107% in CY26 - The Economic Times
-
Ranveer Singh's 'Padmaavat' co-star Aditi Rao Hydari lives with Siddharth in a 4,000 sq ft Chennai home wi - The Economic Times
-
Star Delta Transformers schedules 50th AGM for September 29, 2026 - scanx.trade
Frequently Asked Questions
What is Strides Pharma Science's current stock price?
Strides Pharma Science shares were last quoted at ₹1,095.00 (+0.9% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
What is the P/E ratio of Strides Pharma Science?
Strides Pharma Science has a price-to-earnings (P/E) ratio of 17.79 and a price-to-book (P/B) ratio of 3.33. The industry P/E is 53.33.
What is the 52-week high and low of Strides Pharma Science?
The 52-week high of Strides Pharma Science is ₹1,260.10 and the 52-week low is ₹769.60.
What is the market cap of Strides Pharma Science?
The market capitalisation of Strides Pharma Science is about ₹10,915.09 crore.
How did Strides Pharma Science perform in its latest quarterly results?
In the latest quarter (Jun 2026), Strides Pharma Science reported sales of ₹1,265.00 crore (+12.9%) and net profit of ₹165.00 crore (+55.7%), compared with the same quarter last year.
Is Strides Pharma Science a good stock to buy?
This page is for information and is not investment advice. As per the data shown here, Strides Pharma Science has a 3-year ROE of 57.00%, 3-year profit growth of 71.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
What is the promoter holding in Strides Pharma Science?
Promoters hold about 27.91% of Strides Pharma Science.
Which sector does Strides Pharma Science belong to?
Strides Pharma Science belongs to the Pharmaceuticals & Drugs sector.